Radiotherapy in marginal zone lymphoma

Deinbeck, Kristin Anna; Geinitz, Hans; Haller, Bernhard; Fakhrian, Khashayar

doi:10.1186/1748-717x-8-2

Cited by 12 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[10] So local therapy alone, either surgery or radiotherapy, may be curative. [11] Deinbeck et al, [12] treated 30 marginal zone lymphoma patients with median 40 Gy of radiation. Ninety percentage of these patients had extranodal presentation, and there was no infield recurrence after median 103 months follow-up.…”

Section: Discussionmentioning

confidence: 99%

MALT lymphoma at the base of tongue of a 29-year-old woman treated with radiation therapy alone

et al. 2014

View full text Add to dashboard Cite

Mucosa-associated lymphoid tissue (MALT) lymphoma is frequently reported in the gastrointestinal tract (GIT), but the incidence is low in the upper aerodigestive tract. In particular, MALT lymphoma of the tongue is very rare. Only four cases have been reported in the English literature to date. We report a case of 29-year-old woman who had a past history of peripheral T cell lymphoma of the head and neck and a new mass at the right base of tongue 3 years later. An incisional biopsy of the base of tongue revealed a new pathology, one that of extranodal marginal zone B cell lymphoma (MALT lymphoma). After staging work-up, she was diagnosed to be at the Ann Arbor stage IE. She was treated with 30.6 Gy of radiation therapy alone and there was no recurrence after 3 years follow-up.

show abstract

Section: Discussionmentioning

confidence: 99%

MALT lymphoma at the base of tongue of a 29-year-old woman treated with radiation therapy alone

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Other authors have suggested radiotherapy to play the same role 11. Deinbeck et al 12 reported to have cured 30 patients with marginal zone lymphoma with 40 Gy of radiation. Ueda et al 13 reported extraintestinal MALT lymphoma to have a worse prognosis with multiorgan involvement than gastric MALT lymphoma, even after chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

MALT lymphoma of the base of the tongue: a rare case entity

Iftikhar

Siddiqui²,

Minhas

2016

BMJ Case Reports

View full text Add to dashboard Cite

Lymphoma is a malignant tumour arising from lymphoid tissue, with the majority of cases being in the lymph nodes, however, in 1/4th of cases, these tumours are found in extralymphoid tissue. Lymphoid tissue is also found in organs having mucosa, such as the digestive tract, salivary gland and in tracheal tissue. This collection of lymphoid tissue is known as mucosa-associated lymphoid tissue (MALT), and non-Hodgkin lymphoma involving this extralymphoidal lymph tissue is known as MALT lymphoma. It was first reported by Isaacson and Wright in 1983, however, it was not included as a working diagnosis in clinical use until it was reclassified as ‘marginal zone B-cell lymphoma’ in a 1994 Revised European American Lymphoma (REAL) classification. It is rarely seen in the head and neck region, and we report the sixth case of MALT lymphoma of the base of the tongue. A 61-year-old man presented with dysphagia and the feeling of a lump in his throat for 5 months.

show abstract

“…Brachytherapy has advantages over EBRT in the dose distribution to OARs, and previous RT plan studies that tried to mimic the dose distribution of brachytherapy by IMRT and proton beam demonstrated that EBRT plans were inferior to brachtherapy plans [ 19 ]. Although several studies did not report severe late toxicities [ 12 , 13 ], these studies usually had a short follow-up period with a small number of patients, making them less representative. A recent prospective phase II study reported a 2-year cumulative grade 3 or worse toxicity rate of 26.7%, which was predominantly rectal, and two of the patients had grade 5 fistula formation [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible

et al. 2021

View full text Add to dashboard Cite

Background The purpose of this study was to analyze the treatment efficacy and safety of stereotactic ablative body radiotherapy (SABR) boost for cervical cancer patients not amenable to brachytherapy. Methods A retrospective review of the medical records from single institution of 25 eligible patients was performed. The patients underwent pelvic radiotherapy (RT) in 25 or 28 fractions with a median dose of 45 Gy (range 44–50.4 Gy). SABR boost was delivered after pelvic RT, with a median dose of 25 Gy (range 20–33 Gy), and a median fraction number of 5 (range 4–6). 21 patients with a follow-up period of more than one year were included in the toxicity analysis, and hematuria and hematochezia that occurred later than 3 months after the RT were graded. Results The median follow-up period after radiotherapy was 2.85 years (range 0.33–6.60). The 3-year local control, locoregional control, disease-free survival, and overall survival rates were 80.9%, 75.8%, 40.9%, and 77.1%, respectively. 5 patients experienced grade 3 toxicity (3 genitourinary, 3 gastrointestinal), and no grade 4–5 toxicity was reported. Univariate analysis showed that cumulative D2cc in equivalent dose in 2 Gy fractions (EQD2) of rectum was marginally predictive for any grade of hematochezia (P = 0.051). Cumulative D2cc EQD2 of bladder was not predictive for hematuria. In the receiver operating characteristic (ROC) curve analysis, the optimal threshold of cumulative rectal D2cc EQD2 was 81.2 Gy for any grade of hematochezia. Conclusion SABR boost for cervical cancer was effective and tolerable. Although it cannot substitute brachytherapy, it can be a treatment option when brachytherapy is not possible.

show abstract

Radiotherapy in marginal zone lymphoma

Cited by 12 publications

References 28 publications

MALT lymphoma at the base of tongue of a 29-year-old woman treated with radiation therapy alone

MALT lymphoma at the base of tongue of a 29-year-old woman treated with radiation therapy alone

MALT lymphoma of the base of the tongue: a rare case entity

Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible

Contact Info

Product

Resources

About